AMD expands PsiQuantum partnership and plans an equity investment in the photonic quantum company
Short answer: PsiQuantum and AMD announced on 12 November an expanded strategic partnership to co-design the classical computing that utility-scale, fault-tolerant quantum computers will need, and AMD plans to make an equity investment in PsiQuantum. The size of the stake was not disclosed.
According to the companies' joint announcement, the deal builds on PsiQuantum's earlier choice of AMD Versal FPGA technology for its fault-tolerant platform and widens it to AMD Instinct GPUs, EPYC CPUs and the ROCm software stack, combined with PsiQuantum's silicon photonics. The two say they will also develop hybrid applications that mix quantum, high-performance and AI computing, and plan to share more at the SC26 supercomputing conference in Chicago from 15 to 20 November.
Reuters reported that the companies did not disclose the amount of AMD's planned investment. The agency also said the companies described PsiQuantum's drug discovery workflow as already running on AMD hardware, with early results simulating covalent inhibitors, a class of molecules relevant to oncology drug discovery. Reuters noted that in May the US Commerce Department announced plans for minority stakes in nine quantum companies under a $2 billion CHIPS Act programme, including a $100 million agreement with PsiQuantum.
The partnership follows joint research the two companies published days earlier. QubitWire reported on 11 November that PsiQuantum and AMD researchers had described PRISM, a machine learning decoder for photonic error correction mapped to an AMD VP1902 FPGA, and stressed that the preprint is decoder engineering rather than a working fault-tolerant machine.
